News Briefs

Spending on specialty medications accounted for more than half of total drug spend for the first time last year. That’s according to the Evernorth 2020 Drug Trend Report, released in March, which noted that less than 2% of the population used these drugs. The company also reported that plans participating in its SafeGuardRx programs had lower spending across each of the therapeutic areas. Top conditions for year-over-year trend included inflammatory conditions and cancer. For more information, visit www.evernorth.com/drug-trend-report.

In 2021, 45 states and Washington, D.C., have at least one health insurance plan offered through the Affordable Care Act marketplaces that have a copay accumulator adjustment policy (CAAP), according to a new report by The AIDS Institute. Of those, a CAAP is offered in at least two-thirds of the plans, and of those, a CAAP is included in every plan in 14 states. Legislation prohibiting the policies is in place in five states and Puerto Rico. Researchers also found it difficult to track down information about these policies, including whether they were actually in place. Download the report at https://bit.ly/3upJ090.

Angela Maas

Angela has an extensive background of editing, reporting and writing for trade and consumer publications. She has written Radar on Specialty Pharmacy (formerly called Specialty Pharmacy News) since she joined AIS Health in 2005 and has broad knowledge of the various issues at play within the space. Before joining AIS Health, she was managing editor at Employee Benefit News and Employee Benefit News Canada and managing editor at HemAware (a hemophilia publication), Lupus Living and Momentum (a multiple sclerosis publication). She has a B.A. in English and an M.A. in British literature from Arizona State University.

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/11/WordPress-Featured-Image-radar-on-specialty-pharmacy-Another-Immunotherapy-Indication-Will-Be-Withdrawn.jpg
November 16

FDA Grants Interchangeable Status to Humira Biosimilar; Payers Should Prepare Now for 2023 Launches

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2021/10/WordPress-Featured-Image_NSCLC.jpg
November 16

New Tecartus FDA Approval for Adults With ALL Offers Welcome Therapeutic Option

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2021/11/WordPress-Featured-Image-radar-on-specialty-pharmacy-Specialty-Trend-Increase-Slows-Biosimilars-Are-Having-Impact.jpg
November 16

Prime Therapeutics Launches IntegratedRx – Oncology, Partners on MIP Accreditation

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today